Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 18/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 18/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 18/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 17/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6248001 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CKCNH2 | |
| SCHEMBL20755890 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CKCNH2 | |
| SCHEMBL508648 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CKCNH2 | |
| SCHEMBL4713975 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CKCNH2 | |
| SCHEMBL29369967 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CKCNH2 | |
| SCHEMBL6250732 | 0.92 | PDE4A (0.85) | PDE4APDE4BPDE4DPDE4CKCNH2 | |
| SCHEMBL4718098 | 0.92 | PDE4A (0.85) | PDE4APDE4BPDE4DPDE4CKCNH2 | |
| SCHEMBL5940618 | 0.92 | PDE4A (0.85) | PDE4APDE4BPDE4DPDE4CKCNH2 | |
| SCHEMBL4716894 | 0.91 | PDE4A (0.83) | PDE4APDE4BPDE4DPDE4CKCNH2 | |
| SCHEMBL4717053 | 0.91 | PDE4A (0.83) | PDE4APDE4BPDE4DPDE4CKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2828242-B1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR. | ALMIRALL SA (ES) | 2017-10-04 | — | — | EP | claimed |
| US-9346759-B2 | Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2016-05-24 | — | — | US | claimed |
| US-20150057256-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2--1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYTLATE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL S.A. (ES) | 2015-02-26 | — | — | US | claimed |
| EP-2834219-A1 | SALTS OF 5-[(1R)-2-({2-[4-(2,2-DIFLUORO-2-PHENYLETHOXY)PHENYL]ETHYL}AMINO)-1-HYDROXYETHYL]-8-HYDROXYQUINOLIN-2(1H)-ONE | Almirall S.A. (ES) | 2015-02-11 | — | — | EP | claimed |
| EP-2828242-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR. | Almirall S.A. (ES) | 2015-01-28 | — | — | EP | claimed |
| US-8563731-B2 | Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]jamino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2013-10-22 | — | — | US | claimed |
| WO-2013149959-A1 | SALTS OF 5-[(1R)-2-({2-[4-(2,2-DIFLUORO-2-PHENYLETHOXY)PHENYL]ETHYL}AMINO)-1-HYDROXYETHYL]-8-HYDROXYQUINOLIN-2(1H)-ONE | ALMIRALL, S.A. (ES) | 2013-10-10 | — | — | WO | claimed |
| EP-2647627-A1 | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. | Almirall, S.A. (ES) | 2013-10-09 | — | — | EP | claimed |
| WO-2013139712-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE β2 ADRENERGIC RECEPTOR. | ALMIRALL, S.A. (ES) | 2013-09-26 | — | — | WO | claimed |
| EP-2641900-A1 | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. | Almirall, S.A. (ES) | 2013-09-25 | — | — | EP | claimed |
| EP-2367796-B1 | MESYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO }-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2012-10-24 | — | — | EP | claimed |
| US-20110251234-A1 | MESYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2011-10-13 | — | — | US | claimed |
| EP-2367796-A1 | MESYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO }-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2011-09-28 | — | — | EP | claimed |
| WO-2010072354-A1 | MESYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO }-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE β2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2010-07-01 | — | — | WO | claimed |
| EP-1565464-B1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-07-23 | — | — | EP | claimed |
| US-7238706-B2 | 4-oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROSST CANADA, LTD. (CA) | 2007-07-03 | — | — | US | claimed |
| US-20060258668-A1 | Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders | MERCK & CO., INC. | 2006-11-16 | — | — | US | claimed |
| US-20060058316-A1 | 4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2006-03-16 | — | — | US | claimed |
| US-20050107402-A1 | 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK CANADA INC. (CA) | 2005-05-19 | — | — | US | claimed |
| EP-2265257-B2 | INHALATION COMPOSITION CONTAINING ACLIDINIUM FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ALMIRALL SA (ES) | 2023-10-25 | — | — | EP | disclosed |
| EP-2954889-B1 | INHALATION COMPOSITION CONTAINING ACLIDINIUM FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ALMIRALL SA (ES) | 2022-05-04 | — | — | EP | disclosed |
| EP-2954891-B1 | INHALATION COMPOSITION CONTAINING ACLIDINIUM FOR TREATMENT OF ASTHMA | ALMIRALL SA (ES) | 2022-05-04 | — | — | EP | disclosed |
| US-11000517-B2 | Dosage and formulation | ALMIRALL, S.A. (ES) | 2021-05-11 | — | — | US | disclosed |
| CN-112321579-A | Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2 (1H) -one derivatives | 阿尔米雷尔有限公司 | 2021-02-05 | — | — | CN | disclosed |
| EP-3024489-B1 | SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND BETA-2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES | ALMIRALL SA (ES) | 2020-02-19 | — | — | EP | disclosed |
| US-10456390-B2 | Combinations comprising MABA compounds and corticosteroids | ALMIRALL, S.A. (ES) | 2019-10-29 | — | — | US | disclosed |
| EP-2934594-B1 | CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES . | ALMIRALL SA (ES) | 2019-09-04 | — | — | EP | disclosed |
| US-10300072-B2 | Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | ALMIRALL, S.A. (ES) | 2019-05-28 | — | — | US | disclosed |
| EP-3024459-B1 | COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS | ALMIRALL SA (ES) | 2019-03-27 | — | — | EP | disclosed |
| US-20180303806-A1 | NOVEL DOSAGE AND FORMULATION | ALMIRALL SA (ES) | 2018-10-25 | — | — | US | disclosed |
| US-10085974-B2 | Dosage and formulation | ALMIRALL, S.A. (ES) | 2018-10-02 | — | — | US | disclosed |
| EP-2961407-B1 | SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH 2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES | ALMIRALL SA (ES) | 2018-04-11 | — | — | EP | disclosed |
| US-20180015097-A1 | CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2018-01-18 | — | — | US | disclosed |
| EP-2828242-B1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR. | ALMIRALL SA (ES) | 2017-10-04 | — | — | EP | disclosed |
| US-9757383-B2 | Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | ALMIRALL, S.A. (ES) | 2017-09-12 | — | — | US | disclosed |
| WO-2017076990-A1 | ADDITION SALTS OF N-[4-(4-{[(1S)-1-(5-METHYL-4-OXO-3-PHENYL-3,4-DIHYDROPYRROLO[2,1-F][1,2,4]TRIAZIN-2-YL)ETHYL]AMINO}-7H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-1H-INDOL-6-YL]SULFAMIDE | ALMIRALL, S.A. (ES) | 2017-05-11 | — | — | WO | disclosed |
| US-20170128426-A1 | NOVEL DOSAGE AND FORMULATION | ALMIRALL SA (ES) | 2017-05-11 | — | — | US | disclosed |
| US-9643961-B2 | Cyclohexylamine derivatives having β2 adrenergic antagonist and M3 muscarinic antagonist activities | ALMIRALL, S.A. (ES) | 2017-05-09 | — | — | US | disclosed |
| US-9579316-B2 | Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both muscarinic receptor antagonist and β2 adrenergic receptor agonist activities | ALMIRALL, S.A. (ES) | 2017-02-28 | — | — | US | disclosed |
| US-9562039-B2 | Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activities | ALMIRALL, S.A. (ES) | 2017-02-07 | — | — | US | disclosed |
| US-9549934-B2 | Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | ALMIRALL, S.A. (ES) | 2017-01-24 | — | — | US | disclosed |
| US-9518050-B2 | Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity | ALMIRALL, S.A. (ES) | 2016-12-13 | — | — | US | disclosed |
| EP-2569308-B1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL SA (ES) | 2016-11-23 | — | — | EP | disclosed |
| US-20160303108-A1 | NOVEL DOSAGE FORM AND FORMULATION OF ABEDITEROL | ALMIRALL SA (ES) | 2016-10-20 | — | — | US | disclosed |
| US-20160264557-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2016-09-15 | — | — | US | disclosed |
| US-20160200718-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2016-07-14 | — | — | US | disclosed |
| US-9388189-B2 | Pyrrolotriazinone derivatives as PI3K inhibitors | ALMIRALL, S.A. (ES) | 2016-07-12 | — | — | US | disclosed |
| US-20160175295-A1 | COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS | ALMIRALL, S.A. (ES) | 2016-06-23 | — | — | US | disclosed |
| US-20160166566-A1 | SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2016-06-16 | — | — | US | disclosed |
| EP-3024459-A1 | COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS | Almirall S.A. (ES) | 2016-06-01 | — | — | EP | disclosed |
| EP-3024489-A1 | SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND 2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES | Almirall S.A. (ES) | 2016-06-01 | — | — | EP | disclosed |
| US-20160143915-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2016-05-26 | — | — | US | disclosed |
| US-9346759-B2 | Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2016-05-24 | — | — | US | disclosed |
| US-9340547-B2 | Pyrrolotriazinone derivatives as inhibitors P13K | ALMIRALL, S.A. (ES) | 2016-05-17 | — | — | US | disclosed |
| US-9315463-B2 | Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | ALMIRALL, S.A. (ES) | 2016-04-19 | — | — | US | disclosed |
| EP-2988745-A1 | COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS | Almirall S.A. (ES) | 2016-03-02 | — | — | EP | disclosed |
| EP-2702061-B9 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL SA (ES) | 2016-02-24 | — | — | EP | disclosed |
| US-9254262-B2 | Dosage and formulation | ALMIRALL, S.A. (ES) | 2016-02-09 | — | — | US | disclosed |
| US-20160015704-A1 | COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS | ALMIRALL, S.A. (ES) | 2016-01-21 | — | — | US | disclosed |
| US-20160009698-A1 | SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH β2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2016-01-14 | — | — | US | disclosed |
| US-9233108-B2 | Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | ALMIRALL, S.A. (ES) | 2016-01-12 | — | — | US | disclosed |
| EP-2961407-A1 | SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH 2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES | Almirall S.A. (ES) | 2016-01-06 | — | — | EP | disclosed |
| EP-2954890-A1 | INHALATION COMPOSITION CONTAINING ACLIDINIUM FOR TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Almirall, S.A. (ES) | 2015-12-16 | — | — | EP | disclosed |
| EP-2954889-A1 | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | Almirall, S.A. (ES) | 2015-12-16 | — | — | EP | disclosed |
| EP-2954891-A1 | INHALATION COMPOSITION CONTAINING ACLIDINIUM FOR TREATMENT OF ASTHMA | Almirall, S.A. (ES) | 2015-12-16 | — | — | EP | disclosed |
| US-9206183-B2 | Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-12-08 | — | — | US | disclosed |
| EP-2946768-A1 | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | Almirall, S.A. (ES) | 2015-11-25 | — | — | EP | disclosed |
| EP-2946769-A1 | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | Almirall, S.A. (ES) | 2015-11-25 | — | — | EP | disclosed |
| US-20150329535-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | ALMIRALL, S.A. (ES) | 2015-11-19 | — | — | US | disclosed |
| US-20150306089-A9 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING beta2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2015-10-29 | — | — | US | disclosed |
| EP-2934594-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | Almirall, S.A. (ES) | 2015-10-28 | — | — | EP | disclosed |
| US-20150291595-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2015-10-15 | — | — | US | disclosed |
| EP-2265258-B1 | INHALATION COMPOSITION CONTAINING ACLIDINIUM FOR TREATMENT OF ASTHMA | ALMIRALL SA (ES) | 2015-10-07 | — | — | EP | disclosed |
| US-9133200-B2 | Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-09-15 | — | — | US | disclosed |
| EP-2909207-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | Almirall S.A. (ES) | 2015-08-26 | — | — | EP | disclosed |
| EP-2265257-B1 | INHALATION COMPOSITION CONTAINING ACLIDINIUM FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ALMIRALL SA (ES) | 2015-08-12 | — | — | EP | disclosed |
| EP-2702061-B1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL SA (ES) | 2015-07-29 | — | — | EP | disclosed |
| WO-2015091532-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015091531-A1 | IMIDAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2015-06-25 | — | — | WO | disclosed |
| US-20150140099-A1 | NOVEL DOSAGE FORM AND FORMULATION OF ABEDITEROL | ALMIRALL, S.A. (ES) | 2015-05-21 | — | — | US | disclosed |
| US-9034311-B2 | Pyridin-2(1 H)-one derivatives as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-05-19 | — | — | US | disclosed |
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL SA (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20150118312-A1 | NOVEL DOSAGE AND FORMULATION | ALMIRALL, S.A. (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20150099752-A9 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, SA (ES) | 2015-04-09 | — | — | US | disclosed |
| EP-2854771-A1 | NOVEL DOSAGE FORM AND FORMULATION OF ABEDITEROL | Almirall S.A. (ES) | 2015-04-08 | — | — | EP | disclosed |
| EP-2848615-A1 | New pyrazole derivatives as CRAC channel modulators | Almirall, S.A. (ES) | 2015-03-18 | — | — | EP | disclosed |
| US-20150065471-A1 | SALTS OF 5-[(1R)-2-(AMINO)-1-HYDROXYETHYL]-8-HYDROXYQUINOLIN-2(1H)-ONE | ALMIRALL, S.A. (ES) | 2015-03-05 | — | — | US | disclosed |
| US-20150057256-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2--1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYTLATE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL S.A. (ES) | 2015-02-26 | — | — | US | disclosed |
| WO-2015011245-A1 | COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS | ALMIRALL, S.A. (ES) | 2015-01-29 | — | — | WO | disclosed |
| WO-2015011244-A1 | SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2015-01-29 | — | — | WO | disclosed |
| EP-2828242-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR. | Almirall S.A. (ES) | 2015-01-28 | — | — | EP | disclosed |
| US-20140378421-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING beta2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL SA (ES) | 2014-12-25 | — | — | US | disclosed |
| US-20140343097-A1 | 5-(2-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE FOR THE TREATMENT OF LUNG FUNCTION | ALMIRALL, S.A. (ES) | 2014-11-20 | — | — | US | disclosed |
| US-20140303127-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA 2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL SA (ES) | 2014-10-09 | — | — | US | disclosed |
| US-20140271543-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2014-09-18 | — | — | US | disclosed |
| EP-2776426-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA 2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | Almirall, S.A. (ES) | 2014-09-17 | — | — | EP | disclosed |
| EP-2776425-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | Almirall, S.A. (ES) | 2014-09-17 | — | — | EP | disclosed |
| WO-2014131852-A1 | COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS | ALMIRALL, S.A. (ES) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014131851-A1 | SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH β2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014124757-A1 | PYRROLOTRIAZINE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2014-08-21 | — | — | WO | disclosed |
| WO-2014095920-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | ALMIRALL, S.A. (ES) | 2014-06-26 | — | — | WO | disclosed |
| US-20140170110-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES | ALMIRALL, S.A. (ES) | 2014-06-19 | — | — | US | disclosed |
| US-20140163033-A1 | PYRROLOTRIAZINONE DERIVATIVES AS P13K INHIBITORS | ALMIRALL, SA (ES) | 2014-06-12 | — | — | US | disclosed |
| EP-2739616-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS | Almirall, S.A. (ES) | 2014-06-11 | — | — | EP | disclosed |
| WO-2014060432-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060431-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2014-04-24 | — | — | WO | disclosed |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2014-03-27 | — | — | US | disclosed |
| EP-2702061-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | Almirall S.A. (ES) | 2014-03-05 | — | — | EP | disclosed |
| US-20140038928-A1 | 5-(2--1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2 (1H)-ONE AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES | ALMIRALL, S.A. (ES) | 2014-02-06 | — | — | US | disclosed |
| WO-2013178742-A1 | NOVEL DOSAGE FORM AND FORMULATION OF ABEDITEROL | ALMIRALL, S.A. (ES) | 2013-12-05 | — | — | WO | disclosed |
| EP-2668941-A1 | Novel dosage form and formulation of abediterol | Almirall, S.A. (ES) | 2013-12-04 | — | — | EP | disclosed |
| EP-2666465-A1 | Novel dosage and formulation | Almirall, S.A. (ES) | 2013-11-27 | — | — | EP | disclosed |
| US-20130309200-A1 | IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-11-21 | — | — | US | disclosed |
| US-20130281415-A9 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2013-10-24 | — | — | US | disclosed |
| US-8563731-B2 | Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]jamino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2013-10-22 | — | — | US | disclosed |
| EP-2643321-A1 | IMIDAZO [1,2-B]PYRIDAZINE AND IMIDAZO [4,5-B]PYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2013-10-02 | — | — | EP | disclosed |
| WO-2013139712-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE β2 ADRENERGIC RECEPTOR. | ALMIRALL, S.A. (ES) | 2013-09-26 | — | — | WO | disclosed |
| EP-2641900-A1 | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. | Almirall, S.A. (ES) | 2013-09-25 | — | — | EP | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20130209400-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | BACH TANA JORDI (ES) | 2013-08-15 | — | — | US | disclosed |
| US-20130189317-A1 | NOVEL DOSAGE AND FORMULATION | ALMIRALL, S.A. (ES) | 2013-07-25 | — | — | US | disclosed |
| EP-2398473-B1 | 5-(2-{[6-(2, 2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2-(1H)-one for the treatment of lung function | ALMIRALL SA (ES) | 2013-07-24 | — | — | EP | disclosed |
| US-20130125884-A1 | NOVEL DOSAGE AND FORMULATION | ALMIRALL, S.A. (ES) | 2013-05-23 | — | — | US | disclosed |
| WO-2013068554-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA 2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013068552-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2013-05-16 | — | — | WO | disclosed |
| EP-2592078-A1 | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities | Almirall, S.A. (ES) | 2013-05-15 | — | — | EP | disclosed |
| EP-2592077-A1 | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities | Almirall, S.A. (ES) | 2013-05-15 | — | — | EP | disclosed |
| EP-2582703-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2013-04-24 | — | — | EP | disclosed |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| EP-2569308-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING 2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | Almirall S.A. (ES) | 2013-03-20 | — | — | EP | disclosed |
| US-20130053359-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING beta2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | PRAT QUINONES MARIA (ES) | 2013-02-28 | — | — | US | disclosed |
| WO-2013017461-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-02-07 | — | — | WO | disclosed |
| EP-2554544-A1 | Pyridin-2(1h)-one derivatives as jak inhibitors | Almirall, S.A. (ES) | 2013-02-06 | — | — | EP | disclosed |
| WO-2013010881-A1 | NEW CRTh2 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013010880-A1 | NEW CRTH2 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2013-01-24 | — | — | WO | disclosed |
| EP-2548863-A1 | New CRTh2 antagonists. | Almirall, S.A. (ES) | 2013-01-23 | — | — | EP | disclosed |
| EP-2548876-A1 | New CRTh2 antagonists | Almirall, S.A. (ES) | 2013-01-23 | — | — | EP | disclosed |
| WO-2012160030-A1 | PYRIDIN-2 (1H) -ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES | ALMIRALL, S.A. (ES) | 2012-11-29 | — | — | WO | disclosed |
| EP-2526945-A1 | New CRTH2 Antagonists | Almirall, S.A. (ES) | 2012-11-28 | — | — | EP | disclosed |
| WO-2012146666-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012146667-A1 | IMIDAZOPYRIDINE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2012-11-01 | — | — | WO | disclosed |
| EP-2518071-A1 | Imidazopyridine derivatives as PI3K inhibitors | Almirall, S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| EP-2518070-A1 | Pyrrolotriazinone derivatives as PI3K inhibitors | Almirall, S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| EP-2367796-B1 | MESYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO }-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2012-10-24 | — | — | EP | disclosed |
| EP-2489663-A1 | Compounds as syk kinase inhibitors | Almirall, S.A. (ES) | 2012-08-22 | — | — | EP | disclosed |
| EP-2463289-A1 | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2012-06-13 | — | — | EP | disclosed |
| WO-2012069175-A1 | NEW PYRAZOLE DERIVATIVES HAVING CRTH2 ANTAGONISTIC BEHAVIOUR | ALMIRALL, S.A. (ES) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012069202-A1 | IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL,S.A. (ES) | 2012-05-31 | — | — | WO | disclosed |
| EP-2457900-A1 | New pyrazole derivatives having CRTh2 antagonistic behaviour | Almirall, S.A. (ES) | 2012-05-30 | — | — | EP | disclosed |
| EP-2441755-A1 | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors | Almirall, S.A. (ES) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012041476-A1 | PYRIDINE AND ISOQUINOLINE DERIVATIVES AS SYK- AND JAK-KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2012-04-05 | — | — | WO | disclosed |
| US-20120040941-A1 | 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES | ALMIRALL, S.A. (ES) | 2012-02-16 | — | — | US | disclosed |
| US-20120029014-A1 | 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2 (1H)-ONE FOR THE TREATMENT OF LUNG FUNCTION | ALMIRALL, S.A. (ES) | 2012-02-02 | — | — | US | disclosed |
| EP-2398772-A1 | 5- (2-{ Ý6- (2, 2-DIFLUORO-2-PHENYLETHOXY) HEXYL¨AMINO}-L-HYDROXYETHYL) -8-HYDROXYQUIN OLIN-2 (1H)-ONE AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES | Almirall S.A. (ES) | 2011-12-28 | — | — | EP | disclosed |
| WO-2011157397-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-12-22 | — | — | WO | disclosed |
| EP-2397482-A1 | Heteroaryl imidazolone derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-12-21 | — | — | EP | disclosed |
| WO-2011141180-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2011-11-17 | — | — | WO | disclosed |
| EP-2386555-A1 | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities | Almirall, S.A. (ES) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254356-A1 | Wheel Bearing Apparatus Incorporated With A Wheel Speed Detecting Apparatus | NTN CORPORATION (JP) | 2011-10-20 | — | — | US | disclosed |
| US-20110251234-A1 | MESYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2011-10-13 | — | — | US | disclosed |
| EP-2360158-A1 | Pyrazole derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | disclosed |
| US-20110028442-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2011-02-03 | — | — | US | disclosed |
| US-20110020412-A1 | NOVEL DOSAGE AND FORMULATION | ALMIRALL, S.A. (ES) | 2011-01-27 | — | — | US | disclosed |
| EP-2265258-A2 | INHALATION COMPOSITION CONTAINING ACLIDINIUM FOR TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Almirall, S.A. (ES) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265257-A2 | INHALATION COMPOSITION CONTAINING ACLIDINIUM FOR TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Almirall, S.A. (ES) | 2010-12-29 | — | — | EP | disclosed |
| EP-2254860-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2010-12-01 | — | — | EP | disclosed |
| WO-2010094483-A1 | 5- (2-{ [6- (2, 2-DIFLUORO-2-PHENYLETHOXY) HEXYL] AMINO} -1-HYDROXYETHYL) -8-HYDROXYQUINOLIN-2 (IH)-ONE FOR THE TREATMENT OF LUNG FUNCTION | ALMIRALL, S.A. (ES) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010094484-A1 | 5- (2-{ [6- (2, 2-DIFLUORO-2-PHENYLETHOXY) HEXYL] AMINO}-L-HYDROXYETHYL) -8-HYDROXYQUIN OLIN-2 (1H)-ONE AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES | ALMIRALL, S.A. (ES) | 2010-08-26 | — | — | WO | disclosed |
| EP-2221055-A1 | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function | Almirall, S.A. (ES) | 2010-08-25 | — | — | EP | disclosed |
| EP-2221297-A1 | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases | Almirall, S.A. (ES) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009112273-A2 | NOVEL DOSAGE AND FORMULATION | ALMIRALL, S.A. (ES) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112274-A2 | NOVEL DOSAGE AND FORMULATION | ALMIRALL, S.A. (ES) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009106351-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2009-09-03 | — | — | WO | disclosed |
| EP-1565464-B1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-07-23 | — | — | EP | disclosed |
| EP-1565464-B1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-07-23 | — | — | EP | disclosed |
| US-7342024-B2 | 4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROST CANADA LTD. (CA) | 2008-03-11 | — | — | US | disclosed |
| US-7342024-B2 | 4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROST CANADA LTD. (CA) | 2008-03-11 | — | — | US | disclosed |
| US-7342024-B2 | 4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROST CANADA LTD. (CA) | 2008-03-11 | — | — | US | disclosed |
| US-7238706-B2 | 4-oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROSST CANADA, LTD. (CA) | 2007-07-03 | — | — | US | disclosed |
| US-7238706-B2 | 4-oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROSST CANADA, LTD. (CA) | 2007-07-03 | — | — | US | disclosed |
| US-7238706-B2 | 4-oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROSST CANADA, LTD. (CA) | 2007-07-03 | — | — | US | disclosed |
| US-20060258668-A1 | Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders | MERCK & CO., INC. | 2006-11-16 | — | — | US | disclosed |
| US-20060058316-A1 | 4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2006-03-16 | — | — | US | disclosed |
| EP-1565464-A1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2005-08-24 | — | — | EP | disclosed |
| US-20050107402-A1 | 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK CANADA INC. (CA) | 2005-05-19 | — | — | US | disclosed |
| WO-2004105698-A2 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO., INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004048374-A1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004048374-A1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004048374-A1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (42 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264557-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | PDE4A 483/4885PDE4B 382/4885PDE4D 617/4885 |
| US-20160166566-A1 | SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES | ADRB2, ADRA2C, ADRA2A | PDE4A 1867/4885PDE4B 1929/4885PDE4D 1927/4885 |
| US-10300072-B2 | Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | ADRB2, CHRM3, CHRM2 | PDE4A 445/4885PDE4B 360/4885PDE4D 530/4885 |
| US-20140170110-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES | JAK1, JAK3, JAK2 | PDE4A 2422/4885PDE4B 2659/4885PDE4D 3174/4885 |
| US-20140038928-A1 | 5-(2--1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2 (1H)-ONE AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES | ADRB2, ADRA2C, ADRB1 | PDE4A 1072/4885PDE4B 816/4885PDE4D 1018/4885 |
| US-20140163033-A1 | PYRROLOTRIAZINONE DERIVATIVES AS P13K INHIBITORS | PIP4K2B, PDPK1, PI4KA | PDE4A 873/4885PDE4B 1010/4885PDE4D 1371/4885 |
| US-20120040941-A1 | 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES | ADRB2, ADRA2C, ADRB1 | PDE4A 1153/4885PDE4B 890/4885PDE4D 1151/4885 |
| US-20110251234-A1 | MESYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRA2C, ADRA2A | PDE4A 299/4885PDE4B 367/4885PDE4D 324/4885 |
| US-20150329535-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | CHRM3, CHRM2, ADRB2 | PDE4A 357/4885PDE4B 269/4885PDE4D 339/4885 |
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | PDE4A 1291/4885PDE4B 1733/4885PDE4D 2075/4885 |
| US-20150099752-A9 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | PIK3CD, PIK3CA, PIK3CB | PDE4A 957/4885PDE4B 928/4885PDE4D 1278/4885 |
| US-20160009698-A1 | SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH β2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES | ADRB2, ADRA2C, ADRA2A | PDE4A 2045/4885PDE4B 2225/4885PDE4D 2133/4885 |
| US-20140343097-A1 | 5-(2-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE FOR THE TREATMENT OF LUNG FUNCTION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B2, CYP27A1 | PDE4A 1216/4885PDE4B 926/4885PDE4D 1331/4885 |
| US-20130281415-A9 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | PDE4A 363/4885PDE4B 318/4885PDE4D 504/4885 |
| US-20160175295-A1 | COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS | ADRB2, ADRA2A, ADRA2B | PDE4A 205/4885PDE4B 160/4885PDE4D 326/4885 |
| US-20160015704-A1 | COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS | ADRB2, ADRA2A, ADRA2B | PDE4A 205/4885PDE4B 160/4885PDE4D 326/4885 |
| US-20120029014-A1 | 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2 (1H)-ONE FOR THE TREATMENT OF LUNG FUNCTION | SULT1E1, SULT2A1, UGT1A1 | PDE4A 1240/4885PDE4B 1131/4885PDE4D 1141/4885 |
| US-20150118312-A1 | NOVEL DOSAGE AND FORMULATION | SLC25A20, SLC25A13, SLC38A7 | PDE4A 1235/4885PDE4B 903/4885PDE4D 955/4885 |
| US-20060258668-A1 | Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders | PPP3CA, PTPA, PPP3CB | PDE4A 253/4885PDE4B 268/4885PDE4D 272/4885 |
| US-20150140099-A1 | NOVEL DOSAGE FORM AND FORMULATION OF ABEDITEROL | SLC6A11, SLC6A1, SLC6A13 | PDE4A 1326/4885PDE4B 878/4885PDE4D 966/4885 |
| US-20150291595-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | PIK3CB, PIK3CD, PIK3CA | PDE4A 954/4885PDE4B 1129/4885PDE4D 1562/4885 |
| US-20170128426-A1 | NOVEL DOSAGE AND FORMULATION | SLC25A20, SLC25A13, SLC38A7 | PDE4A 1235/4885PDE4B 903/4885PDE4D 955/4885 |
| US-20150306089-A9 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING beta2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | PDE4A 527/4885PDE4B 412/4885PDE4D 657/4885 |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | PDE4A 1372/4885PDE4B 2181/4885PDE4D 1923/4885 |
| US-20130053359-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING beta2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | PDE4A 390/4885PDE4B 342/4885PDE4D 537/4885 |
| US-20150057256-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2--1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYTLATE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ADRA2C, ADRB2, ADRA2A | PDE4A 367/4885PDE4B 274/4885PDE4D 386/4885 |
| US-20130209400-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | PDE4A 1716/4885PDE4B 1734/4885PDE4D 2138/4885 |
| US-20160303108-A1 | NOVEL DOSAGE FORM AND FORMULATION OF ABEDITEROL | GPBAR1, GCGR, PTGIR | PDE4A 812/4885PDE4B 702/4885PDE4D 1144/4885 |
| US-20180015097-A1 | CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | PDE4A 427/4885PDE4B 350/4885PDE4D 591/4885 |
| US-20160143915-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | PDE4A 483/4885PDE4B 382/4885PDE4D 617/4885 |
| US-20160200718-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | PDE4A 483/4885PDE4B 382/4885PDE4D 617/4885 |
| US-20140378421-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING beta2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | PDE4A 527/4885PDE4B 412/4885PDE4D 657/4885 |
| US-20110028442-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRB1, ADRA2C | PDE4A 353/4885PDE4B 355/4885PDE4D 472/4885 |
| US-20150065471-A1 | SALTS OF 5-[(1R)-2-(AMINO)-1-HYDROXYETHYL]-8-HYDROXYQUINOLIN-2(1H)-ONE | SULT2A1, SULT1E1, SULT1A1 | PDE4A 4246/4885PDE4B 4063/4885PDE4D 3785/4885 |
| US-20140271543-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | PDE4A 2198/4885PDE4B 2381/4885PDE4D 2735/4885 |
| US-10456390-B2 | Combinations comprising MABA compounds and corticosteroids | ADRB2, ADRA2A, ADRA2B | PDE4A 205/4885PDE4B 160/4885PDE4D 326/4885 |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | PDE4A 2708/4885PDE4B 3179/4885PDE4D 3390/4885 |
| US-20130309200-A1 | IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | PDE4A 935/4885PDE4B 1038/4885PDE4D 1706/4885 |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | PDE4A 1716/4885PDE4B 1734/4885PDE4D 2138/4885 |
| US-20050107402-A1 | 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE12 | PDE4A 1/4885PDE4B 2/4885PDE4D 5/4885 |
| US-20140303127-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA 2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | PDE4A 477/4885PDE4B 384/4885PDE4D 590/4885 |
| US-20060058316-A1 | 4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE12 | PDE4A 1/4885PDE4B 2/4885PDE4D 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.